As of November 7, 2026, Royalty Pharma plc is a publicly traded company (Nasdaq: RPRX). The largest holder reporting an active stake on Schedule 13D is Pablo G. Legorreta, the chairman and chief executive, at 18.73%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Morgan Stanley (9.2%), Capital International Investors (8.8%) (Schedule 13D/A, August 17, 2026).
Is this your company?
About to sign with, pay or invest in Royalty Pharma plc? See the free Snapshot first.
Free to see. No signup.
Is Royalty Pharma plc a real, registered company?
- Royalty Pharma plc files with the SEC under CIK 1802768 (its SEC filings).
- Its shares are listed under the ticker RPRX on Nasdaq (SEC company record).
- Incorporated in X0; business address in New York, New York, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ROYALTY PHARMA PLC in our court records and SEC 8-K records (as of 2026-11-07).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Legorreta G. Pablo (filed 2026-08-17).
Who are Royalty Pharma plc's owners and officers?
Royalty Pharma plc: business address in New York, New York; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 4.3% |
| Schedule 13D/A, 2026-08-17 | Legorreta G. Pablo | 18.73% |
| Schedule 13D/A, 2026-06-16 | Severgnini Achille G. | 4.8% |
| Schedule 13G/A, 2026-05-14 | Capital International Investors | 8.8% |
| Schedule 13D/A, 2026-02-20 | Severgnini Achille G. | 5.7% |
| Schedule 13G/A, 2026-02-13 | Capital International Investors | 7.7% |
| Schedule 13G/A, 2025-11-13 | Capital International Investors | 6.6% |
| Schedule 13G/A, 2025-11-05 | Fmr LLC | 6.5% |
| Schedule 13G/A, 2025-10-30 | The Vanguard Group | 2.52% |
| Schedule 13G/A, 2025-08-14 | General Atlantic, L.P. | 3.2% |
| Schedule 13G, 2025-08-13 | Capital International Investors | 5.5% |
| Schedule 13G/A, 2025-08-05 | Morgan Stanley | 9.2% |
Questions about who owns Royalty Pharma plc
Who owns Royalty Pharma plc?
On this page, 3 holders' latest ownership filings report 5% or more of Royalty Pharma plc: Legorreta G. Pablo (18.73%, Schedule 13D/A, filed 2026-08-17), Morgan Stanley (9.2%, Schedule 13G/A, filed 2025-08-05) and Capital International Investors (8.8%, Schedule 13G/A, filed 2026-05-14).
Who are the largest shareholders of Royalty Pharma plc?
By the share each holder's latest filing reports, the largest holders of Royalty Pharma plc on this page are Legorreta G. Pablo (18.73%), Morgan Stanley (9.2%) and Capital International Investors (8.8%).
When did Legorreta G. Pablo buy into Royalty Pharma plc?
The filings give report dates, not purchase dates. The earliest filing from Legorreta G. Pablo on this page is the Schedule 13D/A, filed 2026-08-17, reporting 18.73%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Royalty Pharma plc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Royalty Pharma plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Royalty Pharma plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Royalty Pharma plc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chairman and chief executive: 4,954,404 shares (1.3% of shares outstanding), 1,350,029 held directly and 3,604,375 indirectly (Form 4, 2026-11-06).
- , the executive vice president and investments: 779,915.19 shares (0.20% of shares outstanding), held indirectly through By GWL 2014 G, LLC and 1 other (Form 4, 2025-12-19).
- , the chief financial officer and executive vice president: 307,512 shares (0.08% of shares outstanding), 1,500 held directly and 306,012 indirectly (Form 4, 2026-11-06).
- , the chairman and executive vice president: 300,723 shares (0.08% of shares outstanding), 23,200 held directly and 277,523 indirectly (Form 4, 2026-11-06).
- , a director: 196,348 shares (0.05% of shares outstanding) (Form 4, 2026-06-08).
Shares outstanding: 388,132,400 as of 2020-11-10, from the company's latest SEC cover page.
How much has Royalty Pharma plc raised?
No fundraising or offering filing from Royalty Pharma plc is on file with us.
Keep reading
More on Royalty Pharma plc and the records around it.
Royalty Pharma plc elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- General Atlantic, L.P. also filed stake reports on 10 other companies: Korsana Biosciences, Inc. (Sep 2026), dLocal Ltd (Aug 2026), Pharvaris N.V. (Aug 2026)
- Capital International Investors also filed stake reports on 96 other companies: Aurora Innovation, Inc. (Nov 2026), Arxis, Inc. (Aug 2026), Astronics Corp. (Aug 2026)
- Morgan Stanley also filed stake reports on 182 other companies: MDA Space Ltd. (Nov 2026), RiverNorth/DoubleLine Strategic Opportunity Fund, Inc. (Oct 2026), Arbutus Biopharma Corp (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/royalty-pharma